Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Fusion Pharmaceuticals

10/05/2022 14:17

* Fusion Pharmaceuticals Inc  FUSN.OQ  reported a quarterly
adjusted loss of 46 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 48 cents per share.
    * Revenue was $585.00 thousand​;  analysts expected $1.13
million. 
    * Fusion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 46 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Fusion Pharmaceuticals Inc shares had fallen by 46.8% this
quarter and lost 1.0% so far this year.
    * The company reported a quarterly loss of $19.91 million.
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 01:17 p.m.  ​All
figures in US dollars unless otherwise stated